Dr Reddys Laboratories has scheduled two investor meetings in September 2026 to engage with analysts and institutional investors. The pharma major disclosed the schedule under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The first meeting is set for September 17, 2026, organized by ICICI Securities. This will be an in-person group meet held in Hyderabad between 12:30 pm and 1:30 pm. The second engagement follows a week later on September 24, 2026. Bank of America will organize this virtual group meet, scheduled from 2:00 pm to 3:00 pm.

Meeting Schedule

The company noted that these arrangements are subject to change due to exigencies on the part of investors or the company. K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR, signed the intimation issued on September 10, 2026.

Dr. Reddy's Laboratories Ltd. announced on August 1, 2026, that the U.S. Food and Drug Administration (FDA) has approved its rituximab biosimilar for the U.S. market. This regulatory milestone strengthens the company’s global biosimilars portfolio and expands its presence in the United States, one of the world’s largest pharmaceutical markets. Fresenius Kabi will exclusively commercialize the product in the U.S. under a pre-existing agreement.

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The FDA approval was granted on the agency’s goal date, following a successful Pre-License Inspection (PLI) at Dr. Reddy's biologics manufacturing facility in Bachupally, Hyderabad. Sridevi Khambhampaty, Global Head of Biologics at Dr. Reddy's Laboratories, stated that the approval reflects the company’s capabilities in developing and manufacturing complex biologic medicines for global markets.

Rituximab is a monoclonal antibody targeting the CD20 antigen on B lymphocytes. It is widely used to treat B-cell malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as autoimmune conditions such as rheumatoid arthritis, granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA). The FDA’s decision was supported by comprehensive analytical, non-clinical, and clinical evidence demonstrating that the biosimilar is highly similar to the reference product, Rituxan®, with no clinically meaningful differences in safety, purity, or potency.

Global Commercial Footprint

The rituximab biosimilar is already established in multiple international markets. Dr. Reddy's has commercialized the product in India, the European Union, the United Kingdom, Switzerland, and Canada. Additionally, it holds marketing approvals in more than 25 emerging markets. This broad footprint underscores the company’s strategy to leverage its biosimilars business for both near-term and long-term growth across developed and emerging economies.

What the Numbers Show

The approval of the rituximab biosimilar in the U.S. represents a significant diversification of Dr. Reddy's revenue streams within the high-margin biosimilars segment. With the product already generating sales in over 30 countries, the U.S. entry—facilitated by Fresenius Kabi’s distribution network—positions the company to capture value from one of the most lucrative oncology and immunology markets globally. This move complements Dr. Reddy's existing portfolio of six commercial biosimilar products in India and supports its broader goal of ramping up manufacturing capacity for global expansion.